EGP100
Retatrutide (RETA; LY3437943) is a novel triple agonist of the GIP, GLP-1 and glucagon receptors under investigation for obesity treatment
Retatrutide (RETA; LY3437943) is a novel triple agonist of the GIP, GLP-1 and glucagon receptors under investigation for obesity treatment
Leave feedback about this